Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | XPO1 | O14980 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 3/20 | 0.46 |
| ▸ | STAT6 | P42226 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.44 |
| ▸ | ATF1 | P18846 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 4/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.43 |
| ▸ | RELA | Q04206 | 4/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261389 | 0.90 | JAK3 (0.56) | JAK3JAK2XPO1AURKARPS6KB1 | |
| SCHEMBL22261203 | 0.85 | JAK3 (0.61) | JAK3AURKARPS6KB1STAT6AURKB | |
| SCHEMBL2479323 | 0.82 | JAK2 (0.51) | JAK3JAK2XPO1AURKARPS6KB1 | |
| SCHEMBL22261068 | 0.81 | JAK2 (0.59) | JAK3JAK2AURKARPS6KB1JAK1 | |
| SCHEMBL22261066 | 0.80 | JAK3 (0.56) | JAK3JAK2AURKARPS6KB1JAK1 | |
| SCHEMBL22261240 | 0.80 | JAK3 (0.61) | JAK3JAK2AURKARPS6KB1JAK1 | |
| SCHEMBL22261146 | 0.80 | JAK3 (0.61) | JAK3JAK2JAK1VNN1STAT6 | |
| SCHEMBL23088795 | 0.79 | JAK3 (0.57) | JAK3JAK2JAK1STAT6 | |
| SCHEMBL29622850 | 0.79 | JAK3 (0.57) | JAK3JAK2JAK1STAT6 | |
| SCHEMBL29622795 | 0.78 | JAK3 (0.83) | JAK3JAK2JAK1STAT6AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-11344549-B2 | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3686197-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077489-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885XPO1 3900/4885 |
| US-11344549-B2 | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885XPO1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.